Other formats:
BibTeX
LaTeX
RIS
@article{1461578,
author = {Češková, Eva and Šedová, M. and Kellnerova, R. and Starobová, Olga},
article_location = {BASEL},
article_number = {3-4},
doi = {http://dx.doi.org/10.1159/000492079},
keywords = {Trazodone; Depression; Clinical practice; Treatment-resistant depression; Individualized treatment; Multimodal antidepressant},
language = {eng},
issn = {0031-7012},
journal = {PHARMACOLOGY},
title = {Once-a-Day Trazodone in the Treatment of Depression in Routine Clinical Practice},
url = {https://www.karger.com/Article/FullText/492079},
volume = {102},
year = {2018}
}
TY - JOUR
ID - 1461578
AU - Češková, Eva - Šedová, M. - Kellnerova, R. - Starobová, Olga
PY - 2018
TI - Once-a-Day Trazodone in the Treatment of Depression in Routine Clinical Practice
JF - PHARMACOLOGY
VL - 102
IS - 3-4
SP - 206-212
EP - 206-212
PB - KARGER
SN - 00317012
KW - Trazodone
KW - Depression
KW - Clinical practice
KW - Treatment-resistant depression
KW - Individualized treatment
KW - Multimodal antidepressant
UR - https://www.karger.com/Article/FullText/492079
N2 - Objective: The aim of the study was to evaluate the efficacy, tolerability, and safety of once-a day trazodone tablets (Trittico Prolong (R) 300 mg) in patients with moderate to severe depression in routine clinical practice. Methods: Men and women >= 18 years old with Montgomery-Asberg Depression Rating Scale (MADRS) scores >21 and Clinical Global Impression - Severity (CGI/S) >= 4 were included in this post-authorization, non-interventional, observational prospective safety study, conducted in 8 psychiatric centers in the Czech Republic. The acute treatment phase lasted 5 weeks: 1 week of titration and 4 weeks of full-dose treatment. Patients had follow-up visits 9 and 21 weeks after commencing treatment. Results: Overall, 85 patients were enrolled in the study, of which 80 completed the acute treatment of 5 weeks. There were significant decreases in the overall MADRS score from the baseline mean value of 27.4-21.2 at week 1 (p < 0.001), and a further decrease to 7.9 at week 5 (p < 0.001). The severity of depression according to CGI/S gradually declined. Most patients reported improvement after 6 days of trazodone treatment. The most frequent adverse drug reactions (ADRs) reported were somnolence and fatigue. Conclusions: Trazodone, in the new extended-release formulation, had very good effects in clinical practice, both in previously untreated depressive episodes and in episodes not responsive to previous antidepressive therapy. (C) 2018 S. Karger AG, Basel
ER -
ČEŠKOVÁ, Eva, M. ŠEDOVÁ, R. KELLNEROVA and Olga STAROBOVÁ. Once-a-Day Trazodone in the Treatment of Depression in Routine Clinical Practice. \textit{PHARMACOLOGY}. BASEL: KARGER, 2018, vol.~102, 3-4, p.~206-212. ISSN~0031-7012. Available from: https://dx.doi.org/10.1159/000492079.
|
